STOCK TITAN

NextPlat Warrants (NXPLW) Stock Price, News & Analysis

NXPLW

NextPlat Warrants (NXPLW) last traded on June 2, 2026. A Form 25-NSE filed on June 2, 2026 removes its shares from exchange listing.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
118 172 sessions, May 30, 2025 to June 2, 2026
Largest daily move
+204% close of April 13, 2026
1-year change
-98.6% closing prices, May 30, 2025 to June 2, 2026
1-month change
-67.1% closing prices, May 1, 2026 to June 2, 2026

Company Description

Written before these shares stopped trading.

NextPlat Corp (NASDAQ: NXPL, NXPLW) is described as a global consumer products and services company that provides healthcare and technology solutions through e-commerce and retail channels worldwide. According to multiple company announcements, NextPlat focuses on helping businesses sell goods online domestically and internationally, while also operating healthcare and communications businesses and developing proprietary healthcare analytics software.

Business Overview and Segments

Based on the company’s own descriptions, NextPlat’s business model is built around three core channels:

  • Healthcare services delivered primarily through its PharmcoRx pharmacies and Progressive Care subsidiary, including prescription management and fulfillment, 340B clinic services, and healthcare data management.
  • Communications products and services offered through subsidiaries such as Global Telesat Communications (GTC), Orbital Satcom and Outfitter Satellite, which provide satellite-enabled voice, data, tracking and Internet of Things (IoT) connectivity.
  • E-commerce development programs that support the sale of U.S.-produced products, including health and nutrition brands, into large international markets such as China via major online platforms.

In earlier disclosures, NextPlat also identified two reportable segments: e-Commerce Operations, which involve acquiring and leasing an e-commerce platform, and Healthcare Operations, which provide third-party administration (TPA), data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals and other healthcare-related services. The company describes itself as serving consumers, enterprises, governments and healthcare organizations.

Healthcare Operations and Data Analytics

NextPlat’s healthcare activities are conducted largely in the United States through its PharmcoRx pharmacies and its Progressive Care operation, which it reports having acquired. The company states that its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and partnerships with payors, pharmaceutical manufacturers and distributors. It notes that it offers solutions addressing dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs.

Through its ClearMetrx subsidiary, NextPlat operates a cloud-based healthcare data analytics and reporting platform. ClearMetrx is described as an end-to-end reporting system that streamlines data analytics for physicians, management services organizations (MSOs), 340B entities and pharmacies, and is used across the company’s pharmacies and client network. The company has announced late-stage development of ClearMetrx 4.0, which is expected to integrate artificial intelligence (AI)-enhanced capabilities such as revenue forecasting, predictive inventory management, anomaly and exception detection, audit assistance and analytics, fraud detection and AI-driven what-if simulations. These tools are described as supporting greater efficiency in healthcare operations and improved patient adherence and outcomes.

Communications and IoT Connectivity

In communications, NextPlat reports that it operates an e-commerce communications division offering voice, data, tracking and IoT products and services worldwide. Its Global Telesat Communications (GTC) subsidiary is described as one of Europe’s largest satellite-enabled connectivity providers, serving enterprise, government and consumer customers with satellite and terrestrial connectivity in more than 150 countries.

GTC has entered into a distribution agreement with Telit Cinterion, which NextPlat describes as a global leader in intelligent IoT solutions. Through this agreement, GTC adds advanced 5G connectivity to its existing satellite and terrestrial connectivity suite, targeting industrial and enterprise IoT sectors such as manufacturing, agriculture, transport and logistics, and energy and utilities. The company also references partnerships with commercial satellite network operators, and notes that its communications business generates recurring airtime revenue and supports satellite-enabled IoT solutions.

E-Commerce and Consumer Health Brands

NextPlat states that, through acquisitions, joint ventures and collaborations, it assists businesses in selling their goods online and optimizing their e-commerce presence and revenue. The company highlights an e-commerce development program for China, created to help U.S.-based businesses reach Chinese consumers through platforms such as Alibaba Group’s Tmall and JD.com, as well as social and content channels including Weibo, WeChat and Xiaohongshu.

Under this program, NextPlat has launched its Florida Sunshine brand of premium vitamins and supplements in domestic and international markets, including the United States, the UK and multiple European markets. The company describes Florida Sunshine as a Made-in-USA line of liposomal vitamins formulated to support areas such as immunity, energy, heart health and overall wellness, with initial products including vitamins C and D3 and targeted supplements such as CoQ10 and Lutein. NextPlat reports that it plans to sell Florida Sunshine in China via Tmall Global following platform approval and notes that its e-commerce development program in China has been expanded to additional online and social media channels.

The company also reports an exclusive distribution agreement with OPKO Health, Inc. for the sale of health, nutrition and dietary supplements and animal care products to customers in China, subject to import approvals. According to the company, these products are not subject to certain tariffs on U.S.-produced goods.

Virtual Care and Pharmacy Services

Within healthcare services, NextPlat has announced that its PharmcoRx subsidiary was awarded a multi-state prescription fulfillment contract by DevotedDOc, a virtual medical group. DevotedDOc is described as offering urgent care, medication-assisted treatment (MAT) for opioid use disorder, compounded alternatives to certain GLP-1 therapies for weight loss, and hormone replacement therapy. Under this contract, PharmcoRx provides prescription fulfillment services for patients in Florida and Georgia, and NextPlat notes that PharmcoRx is licensed as a non-resident pharmacy in a number of additional U.S. states.

The company also highlights its 340B clinic services business, where it reports securing new clinic contracts and re-engaging a major client. It has indicated that it has expanded pharmacy operations to offer 24/7 pharmacist services and seven-day-per-week pharmacy operations to support new contracts and customer requirements.

Corporate Structure, Listings and Governance

NextPlat Corp is incorporated in Nevada and, according to its SEC filings, its common stock is listed on The Nasdaq Capital Market under the symbol NXPL, with warrants trading under the symbol NXPLW. The company has reported that it received an extension from Nasdaq to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that it continues to meet other continued listing criteria.

In an 8-K filing, the company reported that its stockholders elect directors and vote on matters such as the appointment of its independent registered public accounting firm and advisory approval of executive compensation. Another 8-K filing documents the appointment of Rodney Barreto as Chairman of the Board and David Phipps as Chief Executive Officer following the passing of the company’s previous Executive Chairman and CEO. The company has also announced leadership changes in finance and healthcare operations and notes ongoing efforts to reduce overhead costs, consolidate office space and streamline operations.

Business Focus and Strategic Themes

Across its public communications, NextPlat emphasizes several recurring themes:

  • Expanding contracted healthcare revenue, including 340B prescriptions and multi-state prescription fulfillment.
  • Growing its communications services customer base and product portfolio, particularly in satellite-enabled connectivity and IoT.
  • Developing and commercializing AI-powered healthcare analytics through ClearMetrx 4.0.
  • Scaling its e-commerce development program to support U.S. brands entering large international markets, including China.
  • Implementing cost reductions, operational process improvements and leadership realignment to support long-term growth.

According to the company’s own descriptions, these activities are intended to support improved operational efficiency, enhanced customer support, and long-term growth across its healthcare, communications and e-commerce channels.

Stock Performance

$0.0024
No recent trading
Last close: June 2, 2026
-98.6%
1 year to June 2, 2026

NextPlat Warrants (NXPLW) closed at $0.0024 on June 2, 2026. In the 12 months to June 2, 2026, the price lost 98.6%.

See what a $1,000 investment in NXPLW would be worth today

Average down calculator for NXPLW

NXPLW Metrics & Rankings

Price returns through June 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

NextPlat Warrants has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include stock split, earnings date, AI. View all NXPLW news →

Financial Highlights

NextPlat Warrants generated $54.3M in revenue in FY2025, retaining a 20.1% gross margin, operating income reached -$9.0M (-16.6% operating margin), and net income was -$10K, reflecting a 0.0% net profit margin. Diluted earnings per share stood at -$0.44. The company generated -$6.1M in operating cash flow. The current ratio was 2.65, measuring current assets divided by current liabilities.

$54.3M
Revenue (FY2025)
-$10K
Net Income (FY2025)
-$6.1M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for NXPLW.

Short Interest History

Last 12 Months

Short interest in NextPlat Warrants (NXPLW) currently stands at 23 shares, down 99.0% from the previous reporting period. Since November 2025, short interest has decreased by 99.1%.

Days to Cover History

Last 12 Months

Days to cover for NextPlat Warrants (NXPLW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

NXPLW Company Profile & Sector Positioning

NextPlat Warrants (NXPLW) .

Investors comparing NXPLW often look at related companies in the same sector, including Henry Schein Inc (HSIC), IBEX Limited (IBEX), Embecta Corp. (EMBC), Surf Air Mobility Inc. (SRFM), and CarParts.com, Inc. (PRTS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate NXPLW's relative position within its industry.

Frequently Asked Questions

NextPlat Warrants (NXPLW) last traded on June 2, 2026. A Form 25-NSE filed on June 2, 2026 removes its shares from exchange listing.

NextPlat Warrants (NXPLW) has no recent trading. Its last close was $0.0024 on June 2, 2026.

The FY2025 revenue of NextPlat Warrants (NXPLW) is $54.3M, from its most recent completed fiscal year.

The FY2025 net income of NextPlat Warrants (NXPLW) is -$10K, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of NextPlat Warrants (NXPLW) is -$0.44 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of NextPlat Warrants (NXPLW) is -$6.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of NextPlat Warrants (NXPLW) is 0.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of NextPlat Warrants (NXPLW) is -16.6% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of NextPlat Warrants (NXPLW) is 20.1% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of NextPlat Warrants (NXPLW), current assets divided by current liabilities, was 2.65 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of NextPlat Warrants (NXPLW) is $10.9M for FY2025, its most recent completed fiscal year.

The operating income of NextPlat Warrants (NXPLW) is -$9.0M for FY2025, its most recent completed fiscal year. Learn about operating income.